Support consumer access to specialty medications through value-based insurance design

The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).    

Study: Smoking cessation products effective

Nicotine replacement therapy (NRT), the antidepressant bupropion, and the drug varenicline can help smokers quit, according to a new systematic review published in The Cochrane Library.